acylated peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Digital Audio Broadcasting (DAB) debuted in some countries in 1998. It transmits audio as a digital signal rather than an analog signal as AM and FM do. DAB has the potential to provide higher quality sound than FM (although many stations do not choose to transmit at such high quality), has greater immunity to radio noise and interference, makes better use of scarce radio spectrum bandwidth and provides advanced user features such as electronic program guides. Its disadvantage is that it is incompatible with previous radios so that a new DAB receiver must be purchased. Several nations have set dates to switch off analog FM networks in favor of DAB / DAB+, notably Norway in 2017 and Switzerland in 2024. A single DAB station transmits a 1,500 kHz bandwidth signal that carries from 9–12 channels of digital audio modulated by OFDM from which the listener can choose. Broadcasters can transmit a channel at a range of different bit rates, so different channels can have different audio quality. In different countries DAB stations broadcast in either Band III (174–240 MHz) or L band (1.452–1.492 GHz) in the UHF range, so like FM reception is limited by the visual horizon to about 40 miles (64 km). HD Radio is an alternative digital radio standard widely implemented in North America. An in-band on-channel technology, HD Radio broadcasts a digital signal in a subcarrier of a station's analog FM or AM signal. Stations are able to multicast more than one audio signal in the subcarrier, supporting the transmission of multiple audio services at varying bitrates.
Semi-closed rebreather technology is sometimes used in diver carried surface supplied gas extenders, mainly to reduce helium use. Some units also function as an emergency gas supply using on-board bailout cylinders: The US Navy MK29 rebreather can extend the duration of the Flyaway Mixed Gas System diving operations by five times while retaining the original mixed-gas storage footprint on the support ship. The Soviet IDA-72 semi-closed rebreather has a scrubber endurance of 4 hours on surface supply, and bailout endurance at 200m of 40 minutes on on-board gas. The US Navy Mark V Mod 1 heliox mixed gas helmet has a scrubber canister mounted on the back of the helmet and an inlet gas injection system which recirculates the breathing gas through the scrubber to remove carbon dioxide and thereby conserve helium. The injector nozzle would blow 11 times the volume of the injected gas through the scrubber.
== Education and career == Zubarev earned a Master of Science in Applied Physics at Moscow Engineering Physics Institute in 1986. He obtained a PhD in ion physics from Uppsala University in 1997, supervised by Bo Sundqvist. After his doctorate, he worked at Cornell University, where in 1997 he co-discovered electron-capture dissociation (ECD) of polypeptides with Fred McLafferty. He later held posts at the University of Southern Denmark and Uppsala University, before becoming professor of medicinal proteomics at Karolinska Institutet.
January 1 – Zohran Mamdani is sworn in as the Mayor of New York City, becoming the first Muslim and Asian American to hold the office. January 3 – The U.S. launches airstrikes on Venezuela and captures Venezuelan president Nicolás Maduro and his wife, Cilia Flores. The operation is named Absolute Resolve. January 4 – 31st Critics' Choice Awards: One Battle After Another and its director Paul Thomas Anderson win Best Picture and Best Director respectively. Films Frankenstein and Sinners and television series Adolescence win four awards each. January 5 Maduro and his wife appear in a federal court in Manhattan and plead not guilty to drugs and weapon charges. New coins celebrating the Semiquincentennial, featuring pilgrims, George Washington, Thomas Jefferson, and James Madison, begin circulating. Minnesota Governor Tim Walz announces he will not seek reelection amidst the Minnesota fraud scandal. The Corporation for Public Broadcasting votes to dissolve itself. The Centers for Disease Control and Prevention rewrites its childhood vaccine schedule, reducing the number of shots universally recommended from 17 to 11.
== Characteristics == Francium is one of the most unstable of the naturally occurring elements: its longest-lived isotope, francium-223, has a half-life of only 22 minutes. The only comparable element is astatine, whose most stable natural isotope, astatine-219 (the alpha daughter of francium-223), has a half-life of 56 seconds, although synthetic astatine-210 is much longer-lived with a half-life of 8.1 hours. All isotopes of francium decay into astatine, radium, or radon. Francium-223 also has a shorter half-life than the longest-lived isotope known of each element up to and including element 105, dubnium. Francium is an alkali metal whose chemical properties mostly resemble those of caesium. A heavy element with a single valence electron, it has the highest equivalent weight of any element. Liquid francium—if created—should have a surface tension of 0.05092 N/m at its melting point. Francium's melting point was estimated to be around 8.0 °C (46.4 °F); a value of 27 °C (81 °F) is also often encountered. The melting point is uncertain because of the element's extreme rarity and radioactivity; a different extrapolation based on Dmitri Mendeleev's method gave 20 ± 1.5 °C (68.0 ± 2.7 °F). A calculation based on the melting temperatures of binary ionic crystals gives 24.861 ± 0.517 °C (76.750 ± 0.931 °F). The estimated boiling point of 620 °C (1,148 °F) is also uncertain; the estimates 598 °C (1,108 °F) and 677 °C (1,251 °F), as well as the extrapolation from Mendeleev's method of 640 °C (1,184 °F), have also been suggested.
Sources: en.wikipedia.org
== Function == Arginase catalyzes the hydrolysis of arginine to ornithine and urea. In addition to arginase-1, there also exists a second type arginase-2, which differs in its tissue distribution, subcellular localization, immunologic crossreactivity and physiologic function. The type I isoform encoded by this gene, is a cytosolic enzyme and expressed predominantly in the liver as a component of the urea cycle. Inherited deficiency of this enzyme results in argininemia, an autosomal recessive disorder characterized by hyperammonemia. Two transcript variants encoding different isoforms have been found for this gene.
=== Planned/unfinished designs === Focke-Wulf Fw 42 – twin-engined medium bomber project developed from the F 19, 1933. Focke-Wulf Ta 183 Huckebein – design for a jet-engined fighter, 1942. Focke-Wulf Fw 206 – planned commercial aircraft, 1940. Focke-Wulf Fw 238 – long-range bomber project (RLM airframe number 8-238 already used by Blohm und Voss) Focke-Wulf Fw 249 – large transport aircraft project; officially designated as Project 195. Focke-Wulf Fw 250 – twin-engine jet fighter project Focke-Wulf Fw 252 – single engine jet fighter Focke-Wulf Ta 254 – proposed version of the Ta 154 fighter. Focke-Wulf Fw 259 Frontjäger (concept) Focke-Wulf Fw 260 – 1960s VTOL airliner proposal Focke-Wulf Fw 261 – four-engine bomber/reconnaissance/U-boat support aircraft project Focke-Wulf Ta 283 – interceptor fighter project Focke-Wulf Fw 300 – proposed long-range version of Fw 200, 1941-1942. Focke-Wulf Ta 400 – Amerikabomber design competitor, never built, 1943. Focke-Wulf Fw P.03.10206 – series of long-range strategic bomber projects, 1944. Focke-Wulf Fw P.03.10221-15 – large capacity strategic transport, 1941. Focke-Wulf Fw P.03.10025 – A 1944 design with a swept wing, a forward-swept V-tail, and two pusher propellers at the rear. Focke-Wulf Fw 03.10251 – series of jet-engined night and bad weather fighters Focke-Wulf Fighter Project w/BMW803 – A 1941 design with a connected twin-boom tail, slightly swept-back wings, and two pusher propellers at the rear.
Safrole is listed as a Table I precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Due to their role in the manufacture of MDMA, safrole, isosafrole, and piperonal are Category I precursors under regulation no. 273/2004 of the European Community. In the United States, safrole is currently a List I chemical. The root bark of American sassafras contains a low percentage of steam-volatile oil, which is typically 75% safrole. Attempts to refine safrole from sassafras bark in mass quantities are generally not economically viable due to low yield and high effort. However, smaller quantities can be extracted quite easily via steam distillation (about 10% of dry sassafras root bark by mass, or about 2% of fresh bark). Demand for safrole is causing rapid and illicit harvesting of the Cinnamomum parthenoxylon tree in Southeast Asia, in particular the Cardamom Mountains in Cambodia. However, it is not clear what proportion of illicitly harvested safrole is going toward MDMA production, as over 90% of the global safrole supply (about 2,000 tonnes or 2,200 short tons per year) is used to manufacture pesticides, fragrances, and other chemicals. Sustainable harvesting of safrole is possible from leaves and stems of certain plants, including the roots of camphor seedlings.
=== Filaments === Nylon filaments are primarily used in brushes especially toothbrushes and string trimmers. They are also used as monofilaments in fishing line. Nylon 610 and 612 are the most used polymers for filaments. Its various properties also make it very useful as a material in additive manufacturing; specifically, as a filament in consumer and professional grade fused deposition modeling 3D printers.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.